- Residency - Johns Hopkins School of Medicine (2002-2005), Neurology
- Internship - Rush-Presbyterian-St. Lukes Med Ctr - GME (2001-2002), Internal Medicine
- Medical School - Baylor College of Medicine (1997-2001)
Benjamin Greenberg, M.D.
- Distinguished Teaching Professor
- Cain Denius Scholar in Mobility Disorders
- Autoimmune Neurology
Benjamin M. Greenberg, M.D., M.H.S., is an Associate Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology and Neurotherapeutics at UT Southwestern Medical Center. He also has an appointment in the Department of Pediatrics.
Dr. Greenberg is an internationally recognized expert in treating rare autoimmune disorders of the central nervous system.
He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology and Neurotherapeutics. He is also the interim Director of the Multiple Sclerosis Center and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children’s Medical Center – which he established as one of only two U.S. programs of its kind.
Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago’s Rush Presbyterian-St. Luke’s Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine, serving as Chief Resident his final year.
He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor’s degree in the history of medicine – both from Johns Hopkins.
Dr. Greenberg splits his clinical time between adult and pediatric patients, routinely consulting on the inpatient units of William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children’s Medical Center.
His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients.
In addition, Dr. Greenberg has led an effort to improve biorepository development and create uniform protocols for sample handling and analysis. As part of this initiative, his collaborative research has identified novel biomarkers that could be key to distinguishing between patients with various neurologic disorders.
Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-director of the nation’s first dedicated Transverse Myelitis Center.
Certified by the American Board of Psychiatry and Neurology, Dr. Greenberg is a three-time Texas Monthly Rising Star and was included in D Magazine's Best Doctors list for 2018. He was also named a Super Doctor by Texas Monthly in 2018.
Meet Dr. Greenberg
Autoimmune Disorders Expert in Dallas
Neurologist Dr. Benjamin Greenberg is an internationally recognized expert in treating adults and children with autoimmune disorders of the central nervous system. He specializes in treating patients with transverse myelitis (TM), neuromyelitis optica (NMO, or Devic’s disease), and multiple sclerosis (MS), as well as children with TM, MS, and other conditions such as autoimmune encephalitis and acute demyelinating encephalomyelitis (ADEM).
Because the diseases are rare, patients can have a hard time finding a medical “home” – a place where the clinicians specialize in treating and better understanding these complex, sometimes debilitating conditions. Dr. Greenberg and the team at UT Southwestern Medical Center offer that home, treating patients from around the world with these disorders.
“It’s been very rewarding to help create a team that has virtually no match in terms of the variety and depth of highly specialized skill sets we offer,” Dr. Greenberg says.
As an example, one common misconception people have about demyelinating diseases is that after an acute event, the recovery time is limited. Some nonspecialists tell patients with transverse myelitis that the function they will recover will be within six to 12 months of the event will be the limit of their recovery.
“Our work and experience has shown us that’s just not the case,” Dr. Greenberg says. “We see adults and children recover function years out from acute events. We often have to remind people that there’s not a time limit on their window for recovery.”
A three-time Texas Monthly Rising Star, Dr. Greenberg believes that UT Southwestern’s multidisciplinary, evidence-based approach is the key to delivering the best care available – both acute and long-term.
“We have a team of experts who are passionate about helping patients with these conditions, and taking an active presence on the national and international stage in understanding and defining treatment options.”
- American Academy of Neurology
- Transverse Myelitis Association (2004), http://myelitis.org
- International Society for Biological and Environmental Repositories (2009)
- D Magazine Best Doctors in Dallas 2016
- University of Texas Southwestern Academy of Teachers 2016
- University of Texas Board of Regents Teaching Award 2015
- 2013 Neurosciences Teaching Award
- 2014 Neurosciences Teaching Award
- 2015 Neurosciences Teaching Award
- 2016 Neurosciences Teaching Award
- 2017 Neurosciences Teaching Award
- Fred Baskin Investigator Award 2011, Research Award
- Frank Ford 2008, Depart of Neurology Teaching Award
- Guy McKhann 2005, Resident Teaching Award
- Service Award From Maryland 2004, Multiple Sclerosis Society
- Intern of the Year Award 2002, Rush Internal Medicine
- 2009 Neurology Teaching Award
- 2010 Neurosciences Teaching Award
- 2011 Neurosciences Teaching Award
- 2012 Neurosciences Teaching Award
Idiopathic Transverse Myelitis: Corticosteroids, Plasma Exchange, or Cyclophosphamide.
Greenberg B, Thomas K, Krishnan C, Kaplin A, Calabresi P, Kerr DNeurology May 2007 68(19) 1614-1617
A blood-based gene expression assay that can identify patients with multiple sclerosis
Greenberg, B., Bigwood, B., Eastman, E.Journal of Neurology June 2008 255(S2) 79
Research Directions in Multiple Sclerosis Therapy
Greenberg B., Calabresi PSeminars in Neurology February 2008 28(1) 121-127
High Dose Cyclophosphamide Reduces Disease Activity in Aggressive Multiple Sclerosis
Krishnan C., Kaplin A., Brodsky R., Drachman D., Jones, R., Pham D., Richert N., Pardo C., Yousem D., Candelario A., Allie R., Hammond E., Quigg M., Trecker C., McArthur J., Johnson R., Nath A., Greenberg B., Calabresi P., Kerr DArchives of Neurology August 2008 65(8) 1044-51
Top-Down Mass Spectrometry on Tissue Extracts and Biofluids with Isoelectric Focusing and Superficially Porous Silica Liquid Chromatography.
Zhang J, Roth MJ, Chang AN, Plymire DA, Corbett JR, Greenberg BM, Patrie SMAnalytical chemistry 2013 Sep
Requirement for safety monitoring for approved MS therapies - An overview.
Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve OClinical and experimental immunology 2013 Sep
Elevated CNS inflammation in patients with preclinical Alzheimer's disease.
Monson NL, Ireland SJ, Ligocki AJ, Chen D, Rounds WH, Li M, Huebinger RM, Munro Cullum C, Greenberg BM, Stowe AM, Zhang RJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2013 Oct
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
Ayers CL, Mendoza JP, Sinha S, Cunnusamy K, Greenberg BM, Frohman EM, Karandikar NJClinical immunology (Orlando, Fla.) 2013 May 147 2 105-19
Blind and Confused.
Sharma VD, Malafronte P, De Simone N, Greenberg BMJAMA neurology 2013 May 1-5
A surprisingly low prevalence of demonstrable stress urinary incontinence and pelvic organ prolapse in women with multiple sclerosis followed at a tertiary neurogenic bladder clinic.
Dillon BE, Seideman CA, Lee D, Greenberg B, Frohman EM, Lemack GEThe Journal of urology 2013 Mar 189 3 976-9
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Frohman TC, Davis SL, Beh S, Greenberg BM, Remington G, Frohman EMNature reviews. Neurology 2013 Jun
Beh SC, Greenberg BM, Frohman T, Frohman EMNeurologic clinics 2013 Feb 31 1 79-138
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.
Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman EJAMA neurology 2013 Feb 70 2 248-51
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Horton L, Conger A, Conger D, Remington G, Frohman T, Frohman E, Greenberg BNeurology 2013 Apr
Expansion of CD27(high) plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation.
Ligocki AJ, Rounds WH, Cameron EM, Harp CT, Frohman EM, Courtney AM, Vernino S, Cowell LG, Greenberg B, Monson NLGenes and immunity 2013 Apr
Human Aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with Neuromyelitis Optica.
Arellano B, Hussain R, Zacharias T, Yoon J, David C, Zein S, Steinman L, Forsthuber T, Greenberg BM, Lambracht-Washington D, Ritchie AM, Bennett JL, Stüve OArchives of neurology 2012 Sep 69 9 1125-31
Epidemiology of neuromyelitis optica in the United States: a multicenter analysis.
Mealy MA, Wingerchuk DM, Greenberg BM, Levy MArchives of neurology 2012 Sep 69 9 1176-80
Cognitive functioning in pediatric transverse myelitis.
Harder LL, Holland AA, Frohman E, Graves D, Greenberg BMMultiple sclerosis (Houndmills, Basingstoke, England) 2012 Nov
Low serum vitamin D levels and recurrent inflammatory spinal cord disease.
Mealy MA, Newsome S, Greenberg BM, Wingerchuk D, Calabresi P, Levy MArchives of neurology 2012 Mar 69 3 352-6
Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman EMultiple sclerosis (Houndmills, Basingstoke, England) 2012 Jul 18 7 1022-6
Current and emerging therapies in multiple sclerosis: a systematic review.
Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D, Orchard M, Greenberg B, Frohman EMTherapeutic advances in neurological disorders 2012 Jul 5 4 205-20
Objective characterization of the relative afferent pupillary defect in MS.
Blazek P, Davis SL, Greenberg BM, Conger A, Conger D, Vernino S, Beh S, Stuve O, Saidha S, Ratchford JN, Green A, Calabresi PA, Balcer LJ, Frohman TC, Frohman EMJournal of the neurological sciences 2012 Dec 323 1-2 193-200
Fatigue, emotional functioning, and executive dysfunction in pediatric multiple sclerosis.
Holland AA, Graves D, Greenberg BM, Harder LLChild neuropsychology : a journal on normal and abnormal development in childhood and adolescence 2012 Dec
Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS.
Frohman AR, Schnurman Z, Conger A, Conger D, Beh S, Greenberg B, Sutter E, Calabresi PA, Balcer LJ, Frohman TC, Frohman EMNeurology 2012 Aug 79 8 797-801
Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.
Ireland SJ, Blazek M, Harp CT, Greenberg B, Frohman EM, Davis LS, Monson NLAutoimmunity 2012 Aug 45 5 400-14
Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis.
Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, Frohman EM, Karandikar NJJournal of autoimmunity 2011 Mar 36 2 115-24
Symptomatic therapy in multiple sclerosis.
Frohman TC, Castro W, Shah A, Courtney A, Ortstadt J, Davis SL, Logan D, Abraham T, Abraham J, Remington G, Treadaway K, Graves D, Hart J, Stuve O, Lemack G, Greenberg B, Frohman EMTherapeutic advances in neurological disorders 2011 Mar 4 2 83-98
Carotid cavernous fistula imitating brainstem glioma.
Clark SW, Dang T, Toth G, Pride GL, Greenberg B, Warnack WArchives of neurology 2011 Feb 68 2 256-7
Optic neuritis: A mechanistic view.
Burton EV, Greenberg BM, Frohman EMPathophysiology : the official journal of the International Society for Pathophysiology / ISP 2011 Feb 18 1 81-92
No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis.
Marder E, Gupta P, Greenberg BM, Frohman EM, Awad AM, Bagert B, Stüve OArchives of neurology 2011 Dec 68 12 1521-5
Treatment of acute transverse myelitis and its early complications.
Greenberg BMContinuum (Minneapolis, Minn.) 2011 Aug 17 4 733-43
Current and emerging multiple sclerosis therapeutics.
Greenberg BM, Khatri BO, Kramer JFContinuum (Minneapolis, Minn.) 2010 Oct 16 5 Multiple Sclerosis 58-77
Associations between retinal nerve fiber layer abnormalities and optic nerve examination.
Cettomai D, Hiremath G, Ratchford J, Venkatesan A, Greenberg BM, McGready J, Pardo CA, Kerr DA, Frohman E, Balcer LJ, McArthur JC, Calabresi PANeurology 2010 Oct 75 15 1318-25
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-? production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.
Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NLEuropean journal of immunology 2010 Oct 40 10 2942-56
Translational research in neurology and neuroscience 2010: multiple sclerosis.
Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, Eagar TNArchives of neurology 2010 Nov 67 11 1307-15
Optical coherence tomography as a potential readout in clinical trials.
Greenberg BM, Frohman ETherapeutic advances in neurological disorders 2010 May 3 3 153-60
Anticipated benefits and surprising effects of daclizumab in multiple sclerosis.
Stüve O, Greenberg BMLancet neurology 2010 Apr 9 4 337-8
Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis.
Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, Kerr D, Greenberg BM, Calabresi PAMultiple sclerosis (Houndmills, Basingstoke, England) 2009 Jun 15 6 735-40
Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study.
Frohman EM, Dwyer MG, Frohman T, Cox JL, Salter A, Greenberg BM, Hussein S, Conger A, Calabresi P, Balcer LJ, Zivadinov RJournal of the neurological sciences 2009 Jul 282 1-2 96-105
Central nervous system infections in the intensive care unit.
Greenberg BMSeminars in neurology 2008 Nov 28 5 682-9
Infectious complications of temporary spinal catheter insertion for diagnosis of adult hydrocephalus and idiopathic intracranial hypertension.
Greenberg BM, Williams MANeurosurgery 2008 Feb 62 2 431-5; discussion 435-6
Future research directions in multiple sclerosis therapies.
Greenberg BM, Calabresi PASeminars in neurology 2008 Feb 28 1 121-7
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, Richert ND, Pardo CA, Yousem DM, Hammond E, Quigg M, Trecker C, McArthur JC, Nath A, Greenberg BM, Calabresi PA, Kerr DAArchives of neurology 2008 Aug 65 8 1044-51
Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide.
Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DANeurology 2007 May 68 19 1614-7
What is the true clinicopathologic spectrum of neuromyelitis optica?-Reply.
Greenberg BM, Wingerchuk D, Mealy M, Levy MJAMA neurology 2013 Feb 70 2 272-3
Interferon Beta and Long-term Disability in Multiple Sclerosis-Reply.
Greenberg BM, Frohman EJAMA neurology 2013 May 70 5 651-3
- Idiopathic Transverse Myelitis: Corticosteroids, Plasma Exchange, or Cyclophosphamide.
- Transverse Myelitis
- Neuromyelitis Optica
- Multiple Sclerosis
- Clinical Treatment Trials
- Biomarkers of Disease
- Autoimmune Neurology